EGFR and non-small cell lung carcinoma: Preclinical and clinical trials have demonstrated significantly improved progression-free survival (PFS) in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) who receive a combination of EGFR tyrosine kinase inhibitors (EGFR-TKIs) and angiogenic therapy.